Many factors are generally considered in prognostication: histological grade, tumor type and size, lymph node metastases, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), but these are insufficient indicators for the proper clinical management of patients [5,6]. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.